Interim report
Page 1
CIN No. L24232PB1983PLC005426 D.L. No. 1800 - OSP , 1804 - B GST No. 03AAACK6458M1ZB I.E. Code No. 1293001210 KWALITY PHARMACEUTICALS LIMITED Regd . Office : Village Nag Kalan , Majitha Road , Amritsar - 143 601 ( INDIA ) Phone : 91-8558820862 ( Accounts ) : 91-8558820863 ( Admin . ) : 91-9915743720 ( Exports ) M.D. Mobile : 91-9814071215 , 9814052314 E - mail : export@kwalitypharma.com ramesh@kwalltypharma.com Website : www.kwalitypharma.com Date : August 10 , 2026 To , The Department of Corporate Services , BSE Limited Phiroze Jeejeebhoy Towers Dalal Street , Mumbai - 400001 Subject : Submission of standalone and consolidated unaudited financial results for the quarter ended on 30.06.2026 under Regulation 33 of the SEBI ( LODR ) Regulations , 2015 Ref : Scrip Code : 539997 With respect to captioned subject , we wish to inform you that the Board of Directors in its Meeting held today has inter - alia , considered and approved the standalone and consolidated Unaudited Financial Results for the quarter ended June 30 , 2026 . We are submitting herewith the standalone and consolidated unaudited financial results under Regulation 33 of the Securities and Exchange board of India ( Listing Obligations and Disclosure Requirements ) Regulations , 2015 , for the quarter ended as on 30.06.2026 along with the Auditors limited review reports thereon . The Board Meeting of the Company commenced at 10:30 a.m. and concluded at 11:55 a.m. Kindly take the above on your record . Yours Faithfully , For KWALITY PHARMACEUTICALS LIMITED LP KWA RAMESH KUMAR Managing Director DIN : 00462656 ROAD INDIA AMRITSAR LTD
Page 2
CIN No. L24232PB1983PLC005426 GST No. 03AAACK6458M1ZB ® D.L. No. 1800-0SP, 1804-B I.E. Code No. 1293001210 0 KWALITY PHARMACEUTICALS LIMITED Regd. Office: Village Nag KaIan, Majitha Road, Amritsar - 143 601 (INDIA) Management Discussion and Analysis — Q1 FY27 Phone : 91-8558820862 (Accounts) : 91-8558820863 (Admin.) : 91-9915743720 (Exports) M.D. Mobile: 91-9814071215, 9814052314 E-mail : export@kwalitypharma.com ramesh@kwalitypharma.com Website : www.kwalitypharma.com Kwality Pharmaceuticals Ltd. ("KPL") delivered a strong start to FY27, extending its track record of disciplined execution, expanding regulatory footprint, and growing presence in complex, high-barrier product segments. In Q1FY27, consolidated revenue grew 46% year-on-year to t162 crore from t112 crore in Q1FY26, and rose 3% QoQ from 157 crore in Q4FY26. EBITDA increased to t 41 crore from 37 crore in Q1FY26, an increase of 13% YoY, with margins expanding from 21.9% to 25.3% (up from 24.8% in Q4FY26), reflecting continued operating leverage and a stronger product mix. PAT surged 119% YoY to 26 crore from t12 crore, with margins improving sharply from 11% to 16%; on a QoQ basis, PAT grew 3% with margins holding steady at 16%. Building on this momentum and a strong FY26 base, management has raised FY27 guidance across all key metrics: revenue to 700+ crore (+39%+ YoY), EBITDA to t189-196+ crore (27-28%+ margin), and PAT to 109+ crore (- 15.5%+ margin). During the quarter, KPL advanced its R&D and clinical programme, completing 13 Bioequivalence (BE) studies — 7 from the General unit, 2 from Beta Lactam, and 4 from Oncology as part of its 40 molecule BE programme (including 3 injectables and 37 OSDs). Filings for completed BE studies have already been made in 15+ countries, with further filings underway, reinforcing KPL's push into regulated markets. The company also secured 15+ new key product registrations during the quarter across Malaysia, Algeria, Peru and Mexico. On the biologics front, KPL received approval to initiate pre-clinical batches for Pembrolizumab, adding a second biologics candidate alongside Erythropoietin, which has now progressed to the clinical trial stage. Construction of the Hormone manufacturing facility remains on schedule, with completion anticipated by November 2026. The company operates five state-of-the-art manufacturing facilities, accredited by premier global regulators such as PIC/S (including ANVISA and SFDA), INVIMA, DIGEMID, and EU-GMP. This robust regulatory foundation establishes KPL as a research-driven front runner in complex and niche injectables, with a presence in over 70+ co
Page 3
CA INDIA CA Amit Handa F.C.A DISA (ICAI), LL.B, LL.M (Partner) 9878887600 Ref: VIJAY MEHRA & CO. CHARTERED ACCOUNTANTS Head Office: D-351, Ranjit Avenue, Amritsar. CA Ashish Raja F.C.A. Dip. IFRS B.Com (Partner) 9899032170 CA Radhika Goel F.C.A , B.com (Hons.) (Partner) 9915460831 Date: I el qj INDEPENDENT AUDITOR'S REVIEW REPORT ON QUARTERLY UNAUDITED STAND .ALONE FINANCIAL RESULTS OF THE COMPANY FOR QUARTER ENDED 30' JUNE , 2026 PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS,2015 (AS AMENDED) To, The Board of Directors of Kwality Pharmaceuticals Limited. I. We have re k ie‘Ned the accompanying - statement of standalone unaudited financial results of ti wality Pharmaceuticals Limited ("the company) for the quarter ended on 30th June , 2026. being submitted b) the Company pursuant to the requirement of Regulation 33 of the SF.131 (Listing Obligations and Disclosure Requirements) Regulations. 2015 (as amended). 2. This Statement. which is the responsibility of the Company's Management and approved b) the Compan)'s Board of Directors. has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting - (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance ‘N. ith Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations. 2015. Our responsibility is to issue a report on the Statement based on our review. 3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity - , issued b) the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an auch e not BRANCH OFFICES: * C-2, UGF, FRONT SIDE, RAJAPURI ROAD, NEAR SHANTI NURSING HOME, UTTAM NAGAR, NEW -110059 10-E, MALVIYA COMPLEX, LANE NEXT TO NO EXIT, MOHAN MALVIYA ROAD, AMRITSAR - 143001 Email : vijaymehraca@gmailcom, caamithanda@gmail.com, caashishra/a09@gmail.com, caradhikagoel@gmail.com
Page 4
CA INDIA CA Amit Handa F.C.A DISA LL.B, LL.M (Partner) 9878887600 VIJAY MEHRA & CO. CHARTERED ACCOUNTANTS Head Office: D-351, Ranjit Avenue, Amritsar. CA Ashish Raja F.C.A. Dip. IFRS B.Com (Partner) 9899032170 111 Ref Date: CA Radhika Goel F.C.A, B.com (Hons.) (Partner) 9915460831 performed an audit and accordingly. we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with applicable Indian Accounting Standards (" Ind AS- ) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement. For VIJAY MEHRA & CO. Chartered Accountants CA \ l' HANDA Partner M. No: 502400 ERN: 001051N UDIN:-26502400AYBZEH2450 BRANCH OFFICES: Place: Amritsar Date: 10-08-2026 C-2, UGF, FRONT SIDE, RAJAPURI ROAD, NEAR SHANTI NURSING HOME, UTTAM NAGAR, NEW DELHI - 110059 10-E, MALVIYA COMPLEX, LANE NEXT TO NO EXIT, MOHAN MALVIYA ROAD, AMRITSAR -143001 Email : vijaymehraca@gmail.com, caamithanda@gmail.com, caashishraja09@gmail.com, caradhikagoel@gmail.com
Page 5
CA Amit Hando F.C.A DISA (ICAO, LL.B, LL.M (Partner) 9878887600 Ref: VIJAY MEHRA & CO. CHARTERED ACCOUNTANTS Head Office: D-351, Ranjit Avenue, Amritsar. CA Ashish Raja F.C.A. Dip. IFRS B.Com (Partner) 9899032170 CA Radhika Goel F.C.A, B.com (Hons.) (Partner) 9915460831 I I ' Date: INDEPENDENT AUDITOR'S REVIEW REPORT ON THE QUARTERLY UNAUDITED CONSOLIDATED FINANCIAL RESULTS OF THE COMPANY FOR THE QUARTER ENDED .301" JUNE, 2026 PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (AS AMENDED) To, The Board of Directors of Kwality Pharmaceuticals Limited. 1. \VC haVe. re \ iew ed the accompanying statement of Consolidated Unaudited Financial Results of Kwality Pharmaceuticals Limited ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss for the quarter ended on 30th June 2026 being submitted by the Parent Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regu!ations. 2015 (as amended). 2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 Interim Financial Reporting- ("Ind AS 34"). prescribed under Section 133 of the Companies Act. 2013. and other accounting_ principles generally accepted in India and in compliance \k ith the Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity-. issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries. primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that w e would become are of all significant matters that might be identified in an audit. Accordingly. we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEI31 under Regulation 33 (8) of the SEW (Listing Obligations and Disclosure Requirements) Regulations. 2015. as amen 141) extent CA HARTERED BRANCH OFFICES: ACCOUNTANTS C-2, UGF, FRONT SIDE, RAJAPURI ROAD, NEAR SHANTI NURSING HO ME, UTTAM NAGAR, -4 .059 10-E, MALVIYA COMPLEX, LANE NEXT TO NO EXIT, MOHAN MALVIYA ROAD, AMRITSA: Email : vijaymehraca@gmail.com, caamithanda@gmail.com, caashishraja09@gmail.com, caradhikagoel@gmail.com ct'0
Page 6
CA INDIA Head Office: D-351, Ranjit Avenue, Amritsar. CA Amit Handa F.C.A DISA (tCAI), LL.B, LL.M (Partner) 9878887600 Ref VIJAY MEHRA & CO. CHARTERED ACCOUNTANTS CA Ashish Raja F.C.A. Dip. IFRS B.Com (Partner) 9899032170 aPP licable. 4. The Statement includes the results of the following entities: Kwality Pharmaceuticals Africa Limitada (Foreign subsidiary) CA Rddhika Goel F.C.A, B.com (Hons.) (Partner) 9915460831 Date: (0141.n) a 5. Based on our re x iew conducted and procedures perthrmed as stated in paragraph 3 above, nothinu, has come to our attention that causes us to believe that the accompanying Statement of consolidated unaudited financial results prepared in accordance with applicable Indian Accounting Standards ("IndAs - ) and lother accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements). Regulations. 2015 .as amended, including the manner in which it is to be disclosed, or that it contains an) material misstatement. 6. Hie consolidated unaudited financial results includes the interim financial statements/ financial information/ financial results of subsidiar) ilia have not been reviewed/audited by us. whose interim financial statements/ financial information/ financial results reflect total revenue of Rs. 0.00 Lacs for the quarter ended 30' June. 2026. total Profit /(loss) after tax of Rs. -0.45 Lacs and total other comprehensive income / loss of Rs. -0.45 Lacs for the quarter ended 30111 June.2026 as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial statements / financial information / financial results are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter. For VIJAY NIEI IRA & CO. Chartered Accountants ( .AMIT HANDA Partner M. No: 502400 FRN: 001051N 26502400‘ 'MIA D1265 BRANCH OFFICES: Place: Amritsar Date: 10-08-2026 C-2, UGF, FRONT SIDE, RAJAPURI ROAD, NEAR SHANTI NURSING HOME, UTTAM NAGAR, NEW DELHI -110059 10-E, MALVIYA COMPLEX, LANE NEXT TO NO EXIT, MOHAN MALVIYA ROAD, AMRITSAR - 143001 Email : vijaymehraca@gmail.com, caamithanda@gmail.com, caashishraja09@gmail.com, caradhlkagoel@gmail.com
Page 7
'OVALLY)," PHARMAC'EUTICALS LIMITED licgd.Offiee.:- % ITIAGE NACK.11.AN, MAJITHA ROAD, AMRITSAR, PINLIAR— J43601 ('IN No. :- L24232PB1983PLC00$426; Phone no. :- 8558820862 - Email 14:- ramesh(ãhwalitypharma.com; Website :- www.kwahtypharrna.com I:naudited Standalone Financial Results for the Quarter Ended 30th June 2026 I in lakhs) Quarter Ended 30.06.2025 (Unaudited) except EPS Year Ended 31.03.2026 (Audited) Sr. No. Particulars ' Quarter . Ended 30.06.2026 (Unaudited) Quarter Ended 31.03.2026 (Audited) I II Revenue from operations (Net) Other income 16235 22 62 27 15682 24 05801 I 1147 00 37 57 50305 80 285 86 III Total Ravaaoe (1+11) 16297.49 15788.04 11185.47 50591.75 IV Expenses (a) Cost of materials consumed (b) P.irchases of stack-in-trade (c) Changes in inventortes of twshed goods. work-in•progress and stock-m-trade (d) Employee benefits expense (e) Finance Cost (I) Depreciation and amortisation expense (v) Other expenses 8533 77 47 06 161 70 1474 29 266 06 499 17 - 1916 28 706786 603 42 6901 1421 57 288 67 526 08 I 74564 499804 797 89 743 1215 27 276 00 475 98 1710 82 24081 02 1734 63 27 77 5403 84 007041 079431 72)582 I tttal ex ,,•rises I IV 1 ' 12898.33 12623.15 9481.44 41559.54 V Profit/fl ass) from operations before Exceptional items and "fax (Ill -IV) 3399.15 3164.89 1704.03 9032.21 VI I .i,eptional Items I--- 00 00 00 82 94 VII Pt old r• (Loss' bethre Tax (V -VI) 3399.15 3164.89 1704.03 8949.27 . VIII Tax expense (1) Current tax (2) Defer] ed tax (1) Income tax ieLttrig, to earlier years 864 07 -2850 00 824 22 -18458 -3 85 41589 74 92 00 2280 03 8870• 23 20 IX Profit tl ass. afiet Tax t VII -V111 2562.68 2529.11 1193.22 6734.66 X Other Comprehensive Income (net of I) IWO'S that will not be reclassified to profit Of loss (ii) Items that will be reclassified to profit or loss 900 00 8 12 00 15 17 00 13 67 00 I eta! Other Comprehensive Income (ne) of tax) 900 3.12 15.37 13.67 XI total Comprebensivelncome fat the pe rod (IX' , X) 2571.68 2537.23 1208.59 6748.33 XII XIII. Paid up Lvov Share Capital (Face talue Rs 10 each) Other Lquity (excluding ecalualion reserve) 1037 62 PM 62 (03762 1037 62 3221062 XIV La111111:S per equity share (Non annualised) ((In Rs ) ( I ) Basle (2) Diluted 24 70 24 70 24 37 24 37 IF 50 Ii 50 64 90 64 90 Date:- 10-08-2026 Place:- Anirltsar FOR KWALITY PHARMACEU ICALS LIMITED RAMESH KIIIVLAR Managing Director DIN: 00462656
Page 8
KWALITV PHARMACEUTICALS LIMITED Regd.Office.:- VILLAGE NAGKALAN, MAJITHA ROAD, AMRITSAR, PUNJAB - 143601 CIN No. :- L24232PB1983PLC005426; Phone no. :- 8558820862 Email Id:- rameSh@kwalitypharma.Com; Website vyWW.kWalitypharrna.com Unaudited Consolidated Financial Results for the Quarter Ended 30th June 2026 (r?in lakhs) except EPS 11 IV VI Particulars Revenue from operations (Net) Other income l'otal Rel enue (1-4-11) ixpenses (a) Cost of materials consumed (b) Purchases of stock-in-trade (et Chanees in inventories of finished goods. AN ork-m-progress and stock-in-trade (d)Employee benefits expense (e )Finance Cost (f) Depreciation and amortisation expense (g) Other expenses Total expenses (IV) Profit before share of profit of equity accounted investees. exceptional items and tax Share of profitAloss) of associates and joint ventures accounted for using equity method (net of income tax) VII Plait before exceptional items and tax Exceptional items IX Profit / (1 oss) beiorc‘ Tax (VII -VIII) Tax expense: (1) Current tax (2) Deferred tax (3) Income tax relating to earlier )• ears (4) MAT Credit (Entitlement)/Utilised Pr olit/(1 oss) alto Tax (IX X) Quarter Ended 30.06.2026 (Unaudited) 1623522 27 16297.49 8533 77 47.06 161 70 1474 39 266 06 499 47 1916 33 12898.78 3398.70 000 Quarter Ended 31.03.2026 (Audited) 15711 36 105.80 Quarter Ended 30.06.2025 (Unaudited) 11147.90 37 57 15817.17 11185.47 7967 86 603 42 96 59 1421,67 288.67 526.43 1745 69 12650.33 3166.83 0 00 3398.70 3166.83 00 3398.70 3166.83 864.97 -28 50 .00 0 00 2562.23 £124?7 - 184 58 -3.85 000 2531.05 4998 04 797 89 7 43 1215.48 276 00 476.46 1711 38 9482.69 1702.78 0 00 - Year Ended 31.03.2026 (Audited) 50308.34 285-86 50594.19 24081.02 1734 63 27.77 5404.26 1097 04 1981,04 7236 28 41562.04 9032.16 000 1702.78 9032.16 82 94 1702.78 8949.21 435 89 74 92 00 0 00 1191.97 2280.03 -88.70 23.29 0.00 6114.60 oktviAc, 4-0) INDIA
Page 9
XII Other Comprehensive Income (i) Items that will not be reclassified subsequently to profit or loss Remeasurement of defined benefit plans(net Tax) (ii) Items that will be reclassified to profit Exchange differences in translating financial statements of 9 00 00 13 67 06 15 37 - 76 1 13 67 - 23 ta‘) 9.00 13.73 15.11 13.44 Total Comprehensive Income for the period 2571.23 2544.78 1207.08 6748.04 ( XI+XII) _J XIII ProtitAloss) attributable to a) Owners of the Company 2562 45 . 2530 10 1192 58 6734 63 b) Non-controlling interests - 22 95 - .61 - 03 -XIV Other comprehensive income attributable to a) Owners of the Company 900 13 73 15 11 13 44 b) Non-controlling interests I XV Total comprehensive income attributable to: a) Owners of the Company 2571 45 2543 83 1207 69 6748 07 h) Non-controlling interests - 22 lb - 6 I - 03 XVI Paid up Equity Share Capital (Face value 1037 62 1037 62 1037 62 1037 62 XVII Other Equity(excluding revaluation reserve) 32041.94 Earnings per equi6, share (Non annualised) XVIII (In Rs.) ( I 1 Basic 24 69 24.39 11,49 64.90 121 Diluted 24 69 24 39 • 11 49 64,90 "Basic and Diluted EPS for all periods except for year ended 31° March 2026 is not annualised Date:- 10-08-2026 Place:- .t mritsar KWALITY PHARMA( •-esivis"...' 1 RAMESH KUMAR Managing Director DIN: 00462656 iNDIA
Page 10
CIN No. L24232PB1983PLC005426 GST No. 03AAACK6458M1ZB D.L. No. 1800-0SP, 1804-B I.E. Code No. 1293001210 KINALITY PHARMACEUTICALS LIMITED Regd. Office: Village Nag KaIan, Majitha Road, Amritsar - 143 601 (INDIA) Notes: Phone : 91-8558820862 (Accounts) : 91-8558820863 (Admin.) : 91-9915743720 (Exports) M.D. Mobile: 91-9814071215, 9814052314 E-mail : exportPkwalitypharma.com ramesh@kwalitypharma.com Website : www.kwalitypharma.com 1. The Financial Results of the Company for the Quarter Ended June 30, 2026 have been reviewed by the Audit Committee on 10th August, 2026 and approved by the Board of Directors of the Company in their meeting held on 10th August, 2026. The statutory auditors have carried out limited review of the results for the quarter ended 30th June, 2026 and have issued an unmodified review report. 2. The Financial Results have been prepared in accordance with the requirements of Indian Accounting Standards 34 "Interim Financial Reporting"("Ind-AS 34") notified under section 133 of the Companies Act, 2013 and Regulation 33 of Securities and Exchange Board of India (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended. 3. The Company is primarily engaged in the business of Pharmaceuticals which is single reportable segment for the quarter ended 30" June, 2026 as per Accounting Standard 17 on segment reporting notified under the Companies (Accounting Standards) Rules 2014 and hence no separate segment reporting is given. 4. Previous period figures have been regrouped/rearranged, wherever necessary, to correspond to current period's presentation. 5. The above Financial Results are also available on our website www kwalltyphanthicom and Stock Exchange website corn. 6. The figures for the quarter ended 31" March 2026 are the balancing figures between the audited figures in respect of the full financial year ended 31" March 2026 and the unaudited published year-to-date figures upto 31" December 2025, being the date of end of the third quarter of the financial year ended 31" March 2026 which were reviewed by the statutory auditors. 7. The Earning per Share ([PS) has been calculated as per Accounting Standard on Earning Per Share (AS 20). Date: 10-08-2026 Place: Amritsar FOR AND ON BEHALF OF THE BOARD For KWALITY PHARMACEUTICALS Ramesh K Managing D DIN: 004626